文献速递介入腹部CTMRUS

不同影像引导方式下肝细胞癌消融治疗疗效与安全性的网状Meta分析

Network meta-analysis of the efficacy and safety of ablation for hepatocellular carcinoma under different imaging guidance.
PubMed 文献 · Clin Radiol · 2025-08-05

该网状Meta分析纳入11项随机对照试验共1206例接受消融治疗的肝细胞癌患者,比较不同影像引导方式的安全性与疗效。结果显示CT引导(OR=1.13)和MRI引导(OR=1.43)的消融疗效显著优于常规超声;CT/MRI组复发率(RR=0.45)和常见不良反应风险(RR=0.42)均显著低于常规超声组。作者结论认为CT或MRI引导的消融是安全有效的治疗方式,需进一步多中心随机临床试验确认。

要点

  • CT引导(OR=1.13)和MRI引导(OR=1.43)消融疗效显著优于常规超声引导。
  • CT/MRI组复发率显著低于常规超声组(RR=0.45,95%CI 0.29–0.67)。
  • CT/MRI组常见不良反应风险显著低于常规超声组(RR=0.42,95%CI 0.22–0.82)。

核心结论

  • 作者结论认为CT或MRI引导的消融是肝细胞癌安全有效的治疗方式,需进一步多中心随机临床试验确认这些发现。

研究设计与样本

  • 研究类型为网状Meta分析,检索PubMed、Embase和Wanfang数据库截至2024年5月发表的相关研究。
  • 纳入11项随机对照试验,共1206例接受不同影像技术引导消融治疗的肝细胞癌患者。
  • 终点指标包括治疗疗效、安全性、局部复发率和生存率。

诊断标准与关键数值

  • 网状Meta分析显示CT引导消融疗效优于常规超声(OR=1.13;95%CI 1.03,1.24;P<0.05)。
  • 网状Meta分析显示MRI引导消融疗效优于常规超声(OR=1.43;95%CI 1.07,1.91;P<0.05)。
  • 常规Meta分析显示CT/MRI组复发率显著低于常规超声组(RR=0.45;95%CI 0.29,0.67;P<0.05)。
  • 安全性分析显示CT/MRI组常见不良反应风险显著低于常规超声组(RR=0.42;95%CI 0.22,0.82;P<0.05)。

临床应用与阅片要点

  • 作者结论认为CT或MRI引导的消融是肝细胞癌安全有效的治疗方式。
  • 作者指出需进一步多中心随机临床试验确认这些发现。

局限性

  • 作者指出需进一步多中心随机临床试验确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Hepatocellular carcinoma (HCC) remains a major global health challenge due to its high mortality rates. Imaging guidance is pivotal in ablation therapy, yet the optimal technique remains unclear, necessitating a comparative analysis. The aim of this network meta-analysis is to evaluate the safety and clinical efficacy of ablation for HCC under different imaging guidance techniques.

MATERIALS AND METHODS: Relevant studies published up to May 2024 were searched in PubMed, Embase, and Wanfang databases, and baseline information and endpoint data were extracted. The endpoints of this meta-analysis included treatment efficacy, safety, local recurrence, and survival rate.

RESULTS: The analysis included 11 randomised controlled trials with a total of 1206 patients undergoing ablation treatment for HCC guided by different imaging techniques. Network meta-analysis results for ablation efficacy showed that ablation guided by computed tomography (CT) (odds ratio [OR]=1.13; 95% confidence interval [CI]: 1.03, 1.24; P<0.05) and magnetic resonance imaging (MRI) (OR=1.43; 95% CI: 1.07, 1.91; P<0.05) was significantly more effective than by conventional ultrasound. Conventional meta-analysis results showed that the recurrence rate in the CT/MRI group was significantly lower than that in the conventional ultrasound group (relative risk [RR] = 0.45; 95% CI: 0.29, 0.67; P<0.05). Safety analysis indicated that the risk of common adverse reactions in the CT/MRI group was significantly lower than in the conventional ultrasound group (RR=0.42; 95% CI: 0.22, 0.82; P<0.05).

CONCLUSION: Ablation guided by CT or MRI is a safe and effective treatment for HCC. Further multicentre randomised clinical trials are needed to confirm these findings.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Chen L, Xu H, Li Q, et al. Network meta-analysis of the efficacy and safety of ablation for hepatocellular carcinoma under different imaging guidance. Clin Radiol. 2025. PMID: 40896973. doi:10.1016/j.crad.2025.107039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。